Debatable aspects of systemic angiitis and autoinfl ammatory diseases
https://doi.org/10.30629/0023-2149-2021-99-4-314-320
Abstract
The new data about immune-infl ammatory rheumatic diseases pathogenesis with the participation of the processes of autoimmunity and autoinfl ammation attract attention to the heterogeneity of systemic angiitis, their nomenclature, classifi cation, pathogenesis and the approaches to the therapy. Recommendations of the second International Chapel Hill Consensus Conference (CHCC2012) and EULAR recommendation (2016, 2018) regarding diagnostics and treatment of SA are discussed. The data of 141 patients with various forms of SA and 18 patients with the diseases, which relate to the group of autoinfl ammatory processes as well as the retrospective analysis of 130 patients with the hyperimmunoglobulinemia E are given.
About the Authors
N. P. Shilkina
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Nataliya P. Shilkina — MD, PhD, DSc, prof., professor, Head of the Department of Propaedeutics of Internal Diseases
150000, Ярославль
I. V. Dryazhenkova
Private healthcare institution «Clinical Hospital „RZhD-Medicine“ of the city of Yaroslavl»
Russian Federation
Russian Federation
150030, Yaroslavl
I. E. Yunonin
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
150000, Ярославль
Zh. E. Chetvertakova
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
150000, Ярославль
References
1. Shilkina N.P. Systemic vasculitides: Some debatable aspects of the problem. Therapeutic Archive. 2015;87(5):100–105. (in Russian). DOI: 10.17116/terarkh2015875100-105
2. Nasonov E.L. The role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018;56(4):19–27. (in Russian). DOI: 10.14412/1995-4484-2018-19-27
3. Salugina S.O., Fedorov E.S., Agafonova E.M. Monogenic auto-infl ammatory diseases in children and adults: what a rheumatologist should know. Rheumatology Science and Practice. 2019;57(2):125–132. (in Russian) DOI: 10.14412/1995-4484-2019-125-132
4. Goldbach-Mansky R., Kastner D.L. Autoinfl ammation: The prominent role of IL-1 in monogenic autoinfl ammatory diseases and implication for common illnesses. J. Allergy Clin. Immunol. 2009;124:1141–51. DOI: 10.1016/j.jaci.2009.11.0161
5. Mukhin N.A., Bogdanova M.V., Rameev V.V., Kozlovskaya L.V. Autoinfl ammatory diseases and kidney involvement. Therapeuticheskii Archive. 2017;89(6):4–20. (in Russian). DOI: 10.14412/terarkh20178964-20
6. Papayannopoulos V., Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009;30(11):513–521. DOI:10.1016/j.it.2009/07.011
7. Salugina S.O., Fedorov E.S., Kuzmina N.N., Kamenets E.A., Zakharova E.Y. Autoinfl ammatory diseases in rheumatology: Russian experience. Rheumatology Science and Practice. 2016;54(3):271–280 (in Russian). DOI: 10.14412/1995-4484-2016-271-280
8. Rame ev V.V., Kozlovskaya L.V. Autoinfl ammatory diseases: general idea, development mechanisms, clinical present. Nephrology. 2012;16(2):49–63. (in Russian). DOI: 10.24884/1561-6274-2012-16-2-49-63
9. 15;1:48–54. (in Russian). DOI: http://dx.doi.org/10.14412/1996-7012-2015-1-48-54
10. Jennette J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides. Arthr. Rheum. 1994;37(2):187–192.
11. Jennette J., Falk R., Bacon P. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthr. Rheum. 2013;65(1):1–11.
12. Novikov P.I. Klassifi catsia I nomenklatura sistemnykh vaskulitovmezhdunarodnyi opit v istoritcheskoi perspective / Novikov P.I. Clas sifi cation and the nomenclature of systemic vaskulitides — international experience in the historical perspective. Klinitcheskaya farmacologiya I terapiya = Clin. Pharmacol. Ther. 2013;22(4):57–64. (in Russian)
13. Beketova TV. The current classifi cation of systemic vasculitides. Therapeutic Archive. 2014;86(5):94–98. (in Russian)]
14. Alekberova Z.S. Behcet’s disease (a lecture). Rheumatology Science and Practice. 2013;51(1):52–58. (in Russian). DOI: 10.14412/1995-4484-2013-1202
15. Alekberova Z.S. Bechcet’s disease: ethnos and familial aggregation. Rheumatology Science and Practice. 2016;54(3):244–246. (in Russian). DOI: 10.14412/1995-4484-2016-244-246
16. Lisitsina T.A., Alekberova Z.S., Goloeva R.G. New guidelines for the management of patients with Behcet’s disease/syndrome (EULAR, 2018). Rheumatology Science and Practice. 2019;57(2):133–141. (in Russian. DOI: 10.14412/1995-4484-2019-133-141
17. Hatemi G., Christensen R., Bang D., Bodaghi B., Celik A.F., For tu ne F., Gaudric J., Gul A., Kötter I., Leccese P., Mahr A., Moots R., Ozguler Y., Richter J., Saadoun D., Salvarani C., Scuderi F., Sfi kakis P.P., Siva A., Stanford M., Tugal-Tutkun I., West R., Yurdakul S., Olivieri I., Yazici H. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann. Rheum. Dis. 2018;77:808–818. DOI: 10.1136/annrheumdis-2018-213225
18. Moiseev S.V., Bulanov N.M., Karovaykina E.A., Nosov N.R., Ma karov E.A., Zykova A.S., Kuznetsov E.I., Borodin O.O., Nikifo rova N.V., Novikov P.I. Sovremennye predstavlenia o bolezni Bekh tcheta / Contemporary concepts about Behcet’s disease. Klini tcheskaya farmacologiya I terapiya = Clin. Pharmacol. Ther. 2018;27(3):58–66. (in Russian)
19. Belov B.S., Egorova O.N., Savushkina N.M., Radenska-Lopovok S.G. Panniculitiy v practike internista / Pan niculitides in an internist practice]. Therapeutic Archive. 2014:88–92. (in Russian)
20. Egorova O.N., Belov B.S., Glukhova S.I., Radenska-Lopovok S.G. Idiopathic lobular panniculitis in rheumatology practice: the authors’own data. Rheumatology Science and Practice. 2018;56(3):339–345. (in Russian). DOI: 10.14412/1995-4484-2018-339-345
21. Krylov M.Y., Egorova O.N., Belov B.S. Genetic aspects of panniculitis in a Russian population: a pilot study. Rheumatology Science and Practice. 2016;54(5):553–556. (in Russian). DOI: 10.14412/1995-4484-2016-553-556
22. Ivanov O.L. Kozhnye vaskuliti (angiiti). V knige: Vaskulity i vasculopatii/Skin vasculitides (angiitises) / In the book: Vasculitides and vasculopaties Yaroslavl: Upper Volga, 1999:479–514.
23. Klinger H. Grenzformen der periarteriitis nodosa. Frank Z Pathol. 1931;42:455–480.
24. Wegener F. Ueber generalisierte septische Gefasserkrankungen. Verh. Deut. Pathol. Ges. 1936;29:202–210.
25. Wegener F. Ueber eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr. Pathol. Anat., 1939;102:30–68.
26. Godman G.C., Churg J. Wegener’s granulomatosis: pathology and review of the literature. Arch. Pathol., 1954,58,533–553.
27. Falk R., Gross W., Guillevin L. et al. Granulomatosis with poly angiitis (Wegener’s granulomatosis): an alternative name for Wegener’s granulomatosis. Arthr. Rheum. 2011;63(4):863–864.
28. Jennette J.C. Nomenclature and classifi cation of vasculitis: les sons learned from granulomatosis with polyangiitis (Wegener’s gra nulomatosis). Clin. Exp. Immunol. 2011,164(1),7–10.
29. Smirnova I.G., Bulanov N.M., Zukova A.S. et al. Seropositivniy i seronegativniy variant granulematosa s poliangiitom: vliyanie ANTSA na klinicheskuyu kartiny i prognoz zabolevaniya/ANCA-positive and ANCA-negative granulomatosis with polyangiitis: infl uence ANTSA on the clinical picture and the forecast of disease. Klinicheskaya farmacologiya I terapiya = Clin. Pharmacol. Ther. 2020;29(1):36–40. (in Russian). DOI 10.32756/0869-5490-2020-36-40
30. Semenkova E.N. Sistemnye vaskulity/Systemic vasculitides. Moscow: Medicine, 1988.239. (In Russian)
31. Novikov P.I., Semenkova E.N., Moiseev S.V. Sovremennaya nomenklatura Systemnikh vaskulitov/Contemporary nomenclature of systemic vaskculitides]. Kliniches kaya farmacologiya I terapiya = Clin. Pharmacol. Ther 2013;22(1):70–74. (in Russian)
32. Zhabina E.S., Moiseev S.V., Novikov P.I., Fedorov K.E. Eosinophilic granulematous poliangiite (Churge–Strauss): clinical versions, diagnostics and treatment. Klinicheskaya farmacologiya i terapiya = Clin. Pharmacol. Ther. 2013;22(5):85–92. (in Russian)
33. Dhaygude A, Erdbruegger U, Haubitz M, Woywodt A. ANCA-associated vasculitis: pathogenesis, novel markers of the disease and emerging therapies. Minerva Urol. Nefrol. 2009;61(4):411–43.
34. Sherimova A.E., Sozarukova M.M., Krasnova Т.N., Proskurina E.V., Novikov P.I., Mukhin N.A. Radical- producing function of neutrophils in patients with ANTSAassociated vasculitides. Klinicheskaya farmacologiya i terapiya = Clin. Pharmacol. Ther. 2017;26(5):37–40. (in Russian)
35. Beketova T.V. The 2016 European (EULAR/ERA-EDTA) recommendations for the diagnosis and management of ANCA-associated systemic vasculitis. Rheumatology Science and Practice. 2017;55(1):12–16. (in Russian). DOI: 10.14412/1995-4484-2017-12-16
36. Nasonova V.A. Clinical characteristic of hemorrhagic vasculitis. Diss. cand. med. sci. Moscow, 1954. (in Russian)
37. Mills J.A., Michel B.A., Bloch D.A. et al. The American college of rheumatology 1990 criteria for the classifi cation of Henoch–Schonlein purpura. Arthr. Rheum. 1990;33(8):1114–1121.
38. Krivosheev O. [Systemnye sosudistye purpury: slozhnye voprosi klassifi katsii i nomenklatury / Systemic vascular purpures: complex questions of classifi cation and nomenclature. Doctor. 2000;5:6–9. (in Russian)
39. Guliaev SV, Strizhakov L.A., Moiseev S.V., Fomin V.V. From Schönlein–Henoch purpura to IgA-vasculitis: pathogenetic aspects of the disease. Therap. arch. 2018;10:109–114. (in Russian). DOI: 10.26442/terakh201890104-114
40. Heineke M.H., Ballering A.V., Jamin A., Ben Mkaddem S., Mon teiro R.C., Van Egmond M. New insights in the pathogenesis of im munoglobulin A vasculitis (Henoch–Schönlein purpura). Auto immun. Rev. 2017;16(12):1246–1253. DOI: 10.1016/j.autrev.2017.10.009
41. Lopez-Mejias R., Castaneda S., Genre F. et al. Genetics of im munoglobulin-A vasculitis (Henoch–Schönlein purpura): An updated review. Autoimmun. Rev. 2018;17(3):301–315. DOI: 10.1016/j.autrev.2017.11.024
42. González-Gay M.A., López-Mejías R., Pina T., Blanco R., Castañeda S. IgA Vasculitis: Genetics and Clinical and Therapeutic anagement. Curr. Rheumatol. Rep. 2018;20(5):24. DOI: 10.1007/s11926-018-0735-3
43. Freeman A.F., Holland S.M. Clinical manifestations, etiology and pathogenesis of the hyper-IgE syndromes. Pediatr. Res. 2009;65:32–37. DOI:10.1203/PDR.0b013e31819dc8c5
44. Tavassoli M., Abolhassani H., Yazdani R., Ghadami M., Azizi G., Abdolrahim Poor Heravi S., Moeini Shad T., Kokabee M., Movahedi M., Abdshahzadeh H., Gharagozlou M., Rezaei N., Esmaeilzadeh H., Aleyasin S., Aghamohammadi A. The fi rst cohort of Iranian patients with hyper immunoglobulin E syndrome: A long-term follow-up and genetic analysis. Pediatr. Allergy Immunol. 2019;30(4):469–478. DOI: 10.1111/pai.13043
45. Haenen F., Alders M., Dierckx E., Schil P.V., Demeulemeester V., Mortier G., Desager K. A STAT3 mutation in hyper-immunoglobulin E syndrome: A case report. J. Pediatr Genet. 2013;2(2):91–6. DOI: 10.3233/PGE-13053
46. Shilkina N.P., Masina I.V., Osipova S.Yu., Klokov A.V. Relapsing polychondritis in rheumatologic practice. Rheumatology Science and Practice. 2018;56(2):253–256. (in Russian). DOI: 10.14412/1995-4484-2018-253-256
47. Shilkina N.P., Baranov A.A., Nasonov E.L., Samoryadova O.B. Immunoglobulin E and defeat of vessels with the rheumatic diseases. Theses of the reports of IV Soviet Union congress of revmatology. Minsk, 1991:193–194. (in Russian)
48. Nasonov E.L. New possibilities of pharmacotherapie for immunoinfl ammatory rheumatic diseases: a focus on inhibitors of interleukin 17. Rheumatology Science and Practice. 2017;55(1):68–86. (in Russian). DOI: 10.14412/1995-4484-2017-68-86
49. Nasonov E.L., Lila A.M. Rituximaband other anti-B cell medications the treatment of immune-mediated infl ammatory rheumatic diseases. Сlin. Farm. Ther. 2019;28(1):7–17. (in Russian). DOI 10.32756/0869-5490-2019-1-7-17
Review
For citations:
Shilkina N.P., Dryazhenkova I.V., Yunonin I.E., Chetvertakova Zh.E. Debatable aspects of systemic angiitis and autoinfl ammatory diseases. Clinical Medicine (Russian Journal). 2021;99(4):314-320. (In Russ.) https://doi.org/10.30629/0023-2149-2021-99-4-314-320
Views:
710
Email this article 